The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: An update

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 4, 2008, Pages 385-392

  Lyssenko, Valeriya ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Beta cell function; Enteroinsular axis; Gene expression; Insulin secretion; Pancreatic islets; Transcription factor 7 like 2

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; TRANSCRIPTION FACTOR 7 LIKE 2; WNT PROTEIN; GLUCOSE; T CELL FACTOR 4; T CELL FACTOR PROTEIN;

ALLELE; AUTOIMMUNE DISEASE; FETUS DEVELOPMENT; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET; PREGNANCY DIABETES MELLITUS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; METABOLISM; PANCREAS ISLET BETA CELL; PHYSIOLOGY; RISK FACTOR; SECRETION;

DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; RISK FACTORS; SECRETORY RATE; TCF TRANSCRIPTION FACTORS; VARIATION (GENETICS);

EID: 54049088180     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328304d970     Document Type: Review

References (73)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-787.
2. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26:76-80.
3. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003; 52:568-572.
4. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320-323.
5. Chandak GR, Janipalli CS, Bhaskar S, et al. Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia 2007; 50:63-67.
6. Damcott CM, Pollin TI, Reinhart LJ, et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006; 55:2654-2659.
7. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355:241-250.
8. Groves CJ, Zeggini E, Minton J, et al. Association analysis of 6,736 U. K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 2006; 55:2640-2644.
9. Horikoshi M, Hara K, Ito C, et al. A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia 2007; 50:747-751.
10. Lehman DM, Hunt KJ, Leach RJ, et al. Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with type 2 diabetes and age of onset in Mexican Americans. Diabetes 2007; 56:389-393.
11. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007; 117:2155-2163.
12. Marzi C, Huth C, Kolz M, et al. Variants of the transcription factor 7-like 2 gene (TCF7L2) are strongly associated with type 2 diabetes but not with the metabolic syndrome in the MONICA/KORA surveys. Horm Metab Res 2007; 39:46-52.
13. Munoz J, Lok KH, Gower BA, et al. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes 2006; 55:3630-3634.
14. Saxena R, Gianniny L, Burtt NP, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006; 55:2890-2895.
15. Prunier C, Hocevar BA, Howe PH. Wnt signaling: physiology and pathology. Growth Factors 2004; 22:141-150.
16. Tannishtha R, Hans C. Wnt signalling in stem cells and cancer. Nature 2005; 434:843-850.
17. Dessimoz J, Bonnard C, Huelsken J, Grapin-Botton A. Pancreas-specific deletion of beta-catenin reveals Wnt-dependent and Wnt-independent functions during development. Curr Biol 2005; 15:1677-1683.
18. Wells JM, Esni F, Boivin GP, et al. Wnt/beta-catenin signaling is required for development of the exocrine pancreas. BMC Dev Biol 2007; 7:4.
19. Heiser PW, Lau J, Taketo MM, et al. Stabilization of beta-catenin impacts pancreas growth. Development 2006; 133:2023-2032.
20. Heller RS, Klein T, Ling Z, et al. Expression of Wnt, Frizzled, sFRP, and DKK genes in adult human pancreas. Gene Expr 2003; 11:141-147.
21. Papadopoulou S, Edlund H. Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes 2005; 54:2844-2851.
22. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT LU, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316:1331-1336.
23. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316:1341-1345.
24. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445:881-885.
25. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316:1336-1341.
26. Cauchi S, Meyre D, Choquet H, et al. TCF7L2 variation predicts hyperglycemia incidence in a French general population: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 2006; 55:3189-3192.
27. Cervin C, Lyssenko V, Bakhtadze E, et al. Genetic similarities between Lada, type 1 and type 2 diabetes. Diabetes 2008; 57:1433-1437.
28. Field SF, Howson JM, Smyth DJ, et al. Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects. Diabetologia 2007; 50:212-213.
29. Shaat N, Lernmark A, Karlsson E, et al. A variant in the transcription factor 7-like 2 (TCF7L2) gene is associated with an increased risk of gestational diabetes mellitus. Diabetologia 2007; 50:972-979.
30. Watanabe RM, Allayee H, Xiang AH, et al. Transcription factor 7-like 2 (TCF7L2) is associated with gestational diabetes mellitus and interacts with adiposity to alter insulin secretion in Mexican Americans. Diabetes 2007; 56:1481-1485.
31. Barber TM, Bennett AJ, Groves CJ, et al. Disparate genetic influences on polycystic ovary syndrome (PCOS) and type 2 diabetes revealed by a lack of association between common variants within the TCF7L2 gene and PCOS. Diabetologia 2007; 50:2318-2322.
32. Parton LE, McMillen PJ, Shen Y, et al. Limited role for SREBP-1c in defective glucose-induced insulin secretion from Zucker diabetic fatty rat islets: a functional and gene profiling analysis. Am J Physiol Endocrinol Metab 2006; 291:E982-E994.
33. SchaferSA,Tschritter O, Machicao F, et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007; 50:2443-2450.
34. Huertas-Vazquez A, Plaisier C, Weissglas-Volkov D, et al. TCF7L2 is associated with high serum triacylglycerol and differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. Diabetologia 2008; 51:62-69.
35. Mani A, Radhakrishnan J, Wang H, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007; 315:1278-1282.
36. Freathy RM, Weedon MN, Bennett A, et al. Type 2 diabetes TCF7L2 risk genotypes alter birth weight: a study of 24,053 individuals. Am J Hum Genet 2007; 80:1150-1161.
37. Cauchi S, Meyre D, Choquet H, et al. TCF7L2 rs7903146 variant does not associate with smallness for gestational age in the French population. BMC Med Genet 2007; 8:37.
38. Rulifson IC, Karnik SK, Heiser PW, et al. Wnt signaling regulates pancrea-tic beta cell proliferation. Proc Natl Acad Sci USA 2007; 104:6247-6252.
39. Shu L, Sauter NS, Schulthess FT, et al. TCF7L2 regulates p-cell survival and function in human pancreatic islets. Diabetes 2008; 57:645-653.
40. Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta-cell proliferation. J Biol Chem 2008; 283:8723-8735.
41. Cauchi S, Meyre D, DinaC, et al. Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 2006; 55:2903-2908.
42. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
43. Desai M, Zeggini E, Horton VA, et al. An association analysis of the HLA gene region in latent autoimmune diabetes in adults. Diabetologia 2007; 50:68-73.
44. Horton V, Stratton I, Bottazzo GF, et al. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Diabetologia 1999; 42:608-616.
45. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48:150-157.
46. Buchanan TA. Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 2001; 86:989-993.
47. Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet Med 2004; 21:103-113.
48. Shaat N, Groop L. Genetics of gestational diabetes mellitus. Curr Med Chem 2007; 14:569-583.
49. Shaat N, Ekelund M, Lernmark A, et al. Association of the E23K polymorphism in the KCNJ11 gene with gestational diabetes mellitus. Diabetologia 2005; 48:2544-2551.
50. Shaat N, Karlsson E, Lernmark A, et al. Common variants in MODY genes increasethe risk ofgestational diabetes mellitus. Diabetologia 2006; 49:1545- 1551.
51. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774-800.
52. Yilmaz M, Ergun MA, Karakoc A, et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22:336-342.
53. Yilmaz M, Ergun MA, Karakoc A, et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome. Gynecol Endocrinol 2005; 21:206-210.
54. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalenceofimpaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141-146.
55. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in poly-cystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84:165-169.
56. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91:301-307.
57. Meier JJ, Deacon CF, Schmidt WE, et al. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 2007; 50:806-813.
58. Granhall C, Rosengren AH, Renstrom E, Luthman H. Separately inherited defects in insulin exocytosis and beta-cell glucose metabolism contribute to type 2 diabetes. Diabetes 2006; 55:3494-3500.
59. Kirchhoff K, Machicao F, Haupt A, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 2008; 51:597-601.
60. Brack AS, Conboy MJ, Roy S, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 2007; 317:807-810.
61. Liu H, Fergusson MM, Castilho RM, et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007; 317:803-806.
62. Kirstetter P, Anderson K, Porse BT, et al. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol 2006; 7:1048-1056.
63. Scheller M, Huelsken J, Rosenbauer F, et al. Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol 2006; 7:1037-1047.
64. Folsom AR, PankowJS, Peacock JM, et al. Variation inTCF7L2 and increased risk of colon cancer: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2008; 31:905-909.
65. Lim JM, Lee BC, Lee ES, et al. In vitro maturation and in vitro fertilization of bovine oocytes cultured in a chemically defined, protein-free medium: effects of carbohydrates and amino acids. Reprod Fertil Dev 1999; 11:127-132.
66. Wrenzycki C, Herrmann D, Keskintepe L, et al. Effects of culture system and protein supplementation on mRNA expression in preimplantation bovine embryos. Hum Reprod 2001; 16:893-901.
67. Lonergan P, Rizos D, Gutierrez-Adan A, et al. Temporal divergence in the pattern of messenger RNA expression in bovine embryos cultured from the zygote to blastocyst stage in vitro or in vivo. Biol Reprod 2003; 69:1424-1431.
68. Tesfaye D, Ponsuksili S, Wimmers K, et al. A comparative expression analysis of gene transcripts in postfertilization developmental stages of bovine embryos produced in vitro or in vivo. Reprod Domest Anim 2004; 39: 396-404.
69. Hasler JF. In-vitro production of cattle embryos: problems with pregnancies and parturition. Hum Reprod 2000; 15 (Suppl 5):47-58.
70. Meyer UA. Pharmacogenetics: five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5:669-676.
71. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350:1838-1849.
72. Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362:1275-1281.
73. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 56:2178-2182.